Doximity, Inc. $DOCS Stock Acquired by Riverbridge Partners LLC

Riverbridge Partners LLC boosted its stake in shares of Doximity, Inc. (NYSE:DOCS) by 7.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 303,539 shares of the company’s stock after buying an additional 22,320 shares during the period. Riverbridge Partners LLC’s holdings in Doximity were worth $8,602,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Carmignac Gestion lifted its stake in Doximity by 127.8% in the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock valued at $100,480,000 after buying an additional 2,418,971 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Doximity by 29.4% during the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after acquiring an additional 694,300 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Doximity by 24.7% during the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after acquiring an additional 621,464 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Doximity during the third quarter worth $28,858,000. Finally, Bank of America Corp DE raised its holdings in shares of Doximity by 31.8% during the first quarter. Bank of America Corp DE now owns 1,142,530 shares of the company’s stock worth $26,621,000 after acquiring an additional 275,650 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DOCS has been the topic of several research reports. Wolfe Research raised shares of Doximity to an “outperform” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Doximity in a research note on Friday, November 6th. Wells Fargo & Company lowered Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price target on the stock. in a report on Monday, August 10th. Finally, Piper Sandler restated an “overweight” rating and issued a $47.00 price target (up from $42.00) on shares of Doximity in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $30.45.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Doximity Stock Down 1.3%

Shares of DOCS opened at $32.45 on Wednesday. The stock has a market capitalization of $5.78 billion, a P/E ratio of 45.07, a P/E/G ratio of 34.25 and a beta of 1.29. Doximity, Inc. has a twelve month low of $17.15 and a twelve month high of $54.04. The company has a 50 day moving average of $29.33 and a 200-day moving average of $25.43.

Doximity (NYSE:DOCS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.17. The company had revenue of $174.54 million for the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. Doximity’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business earned $0.45 earnings per share. On average, sell-side analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Doximity

In other Doximity news, Director Watkin Phoebe L. Yang sold 1,290 shares of Doximity stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the sale, the director directly owned 24,744 shares in the company, valued at approximately $660,912.24. The trade was a 4.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy S. Cabral sold 10,721 shares of Doximity stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director owned 8,084 shares in the company, valued at $282,940. The trade was a 57.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 24,471 shares of company stock worth $761,545. Company insiders own 31.80% of the company’s stock.

Doximity Company Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.